Award: CAMPAIGN \ C30. Public Affairs

Asia Pacific is on the cusp of the Precision Era of medicine, a shift that could improve outcomes, strengthen economies and transform care. Fueled by over 4,000 precision therapies in development, from cell and gene therapies to targeted antibodies, drug-device combinations and advanced diagnostics, healthcare is moving from one-size-fits-all to targeted treatment. But APAC risks being left behind. Reimbursement and regulation are lagging, infrastructure is uneven, and awareness among policymakers, payers, clinicians and the public remains low. This is concerning in a region that accounts for half the world’s cancer cases and about 258 million people living with rare diseases. Without a clear roadmap and stronger evidence base, patients and societies may miss out on the benefits of this new era. On the Cusp of a Cure is a multi-year initiative by L.E.K. Consulting and GCI Health, sponsored by Johnson & Johnson, to shape policy and unlock APAC’s potential.